Ustekinumab treatment principle

Ustekinumab (Ustekinumab) is a humanIgG1ћ monoclonal antibody that specifically binds to the p40 protein subunit used by IL-12 and IL-23 cytokines. IL-12 and IL-23 are naturally occurring cytokines involved in inflammation and immune responses. In in vitro models, ustekinumab works by disrupting the interaction of these cytokines with the shared cell surface receptor chain IL-12Rβ1. The cytokines IL-12 and IL-23 are considered important factors in chronic inflammation, a hallmark of Crohn's disease and ulcerative colitis. Genetic deletion or antibody blockade of the p40 subunit of IL-12 and IL-23 (the target of ustekinumab) showed protection in animal models of colitis.